NCT06196996招募中不适用
Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus: A Clinical Study Evaluating Safety and Efficacy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Time in Range
研究概览
简要总结
This is a single-center, single-arm Phase Investigational Intervention Trial (IIT) clinical trial aimed at evaluating the safety and efficacy of allogeneic regenerative islet transplantation for the treatment of brittle type 1 diabetes mellitus. Eighteen patients with brittle type 1 diabetes mellitus, who have inadequate blood glucose control despite intensified exogenous insulin therapy, will be enrolled. The primary endpoint is defined as the safety and improvement in blood glucose levels of the 12 months after allogeneic regenerative islet transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 6-65 years, gender not specified.
- •Despite intensified exogenous insulin therapy, blood glucose control remains inadequate [glycated hemoglobin ≥7.5%, or TIR (time in range) <70%].
- •Able and willing to use the blood glucose meter provided by the sponsor, conduct self-blood glucose monitoring as required, and complete the patient log as instructed.
- •Fertile eligible subjects (male or female) must agree to use a reliable contraceptive method (hormonal or barrier method or abstinence) during the trial and for at least 90 days after the last dose; premenopausal female patients must have a negative pregnancy test before enrollment.
- •Diagnosed with type 1 diabetes for at least 1 year based on the World Health Organization (WHO) disease diagnostic criteria, and at least one positive result for diabetes-related autoantibodies [glutamic acid decarboxylase autoantibody (GADA), insulinoma-associated-2 autoantibody (IA-2A), insulin autoantibody (IAA), islet cell antibody (ICA), zinc transporter 8 antibody (ZaT8A)]. Experiencing two or more severe hypoglycemic events in the past year, with at least one severe hypoglycemic event in the past 3 months (severe hypoglycemia defined as blood glucose below 2.9 mmol/L or inability to self-correct during hypoglycemia).
- •Voluntarily participate and sign the informed consent form.
排除标准
- •Uncontrolled systemic infections, including but not limited to pulmonary tuberculosis, active hepatitis, a history of positive human immunodeficiency virus (HIV) testing, and positive syphilis treponemal antibody (TP);
- •Presence of significant organic lesions in vital organs such as the heart, lungs, or brain;
- •Complications of severe diabetes, including but not limited to retinal hemorrhage, diabetic foot, etc.;
- •Liver function tests with total bilirubin, ALT, and AST ≥2×ULN, and failure to normalize after drug treatment;
- •Untreated cancer or less than 1 year since cure;
- •Severe gastrointestinal dysfunction, gastrointestinal immune diseases, and inability to take immunosuppressant;
- •History of smoking, alcohol abuse, or drug misuse;
- •Severe mental or psychological disorders;
- •Various advanced metabolic diseases (such as hyperuricemia, etc.);
- •Participation in other clinical trials in the 3 months prior to enrollment;
- •Patients requiring long-term oral/intravenous administration of high-dose glucocorticoids due to various diseases;
- •Pregnant or lactating women;
- •Investigator judgment indicating clear evidence of severe, active, uncontrolled endocrine or autoimmune abnormalities other than type 1 diabetes;
- •Other situations judged by the investigator as unsuitable for participation in the trial.
结局指标
主要结局
Time in Range
时间窗: up to 12 months
Changes in patient blood glucose time in range from baseline
HbA1c
时间窗: up to 12 months
Changes in patient HbA1c levels from baseline during the study period
C-peptide
时间窗: up to 12 months
Changes in patient fasting and postprandial C-peptide/insulin from baseline during the study period
insulin
时间窗: up to 12 months
Changes in patient fasting and postprandial insulin from baseline during the study period
次要结局
- Dose of exogenous insulin(up to 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Autologous Regenerative Islet Transplantation for Insulin-dependent DiabetesDiabetesNCT05294822Shanghai Changzheng Hospital20
Unknown
2 期
Allogeneic Islet Transplantation for the Treatment of Type 1 DiabetesPatients With Type 1 DiabetesNCT01974674Assistance Publique - Hôpitaux de Paris19
进行中（未招募）
1 期
Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive RegimenDiabetes MellitusNCT00706420City of Hope Medical Center17
已完成
不适用
Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney TransplantationOrgan TransplantationImmunosuppressionType 1 DiabetesNCT01123187University Hospital, Lille14
尚未招募
1 期
Clinical apprication of auto-islet transplantation for the patients recieved total pancreatectomy with non-malignant pancreatic tumorbenign pancreatic tumor, chronic pancreatitis, traumatic injury of the pancreasJPRN-UMIN000007119Tokushima univ10